<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152591</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066X2205</org_study_id>
    <secondary_id>2017-001373-16</secondary_id>
    <nct_id>NCT03152591</nct_id>
  </id_info>
  <brief_title>Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome</brief_title>
  <acronym>PCOS</acronym>
  <official_title>A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether LIK066 can be developed for the treatment of
      polycystic ovary syndrome (PCOS) in overweight and obese women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Anticipated">May 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average morning fasting free testosterone blood concentrations from baseline</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in luteinizing hormone (LH) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in follicle stimulating hormone (FSH) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sex hormone binding globulin (SHBG) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in androstenedione at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in dehydroepiandrostenedione (DHEA) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in dehydroepiandrostenedione sulfate (DHEAS) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total testosterone, at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in free androgen index (FAI), at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>LIK066</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>LIK066 tablets for oral administration</description>
    <arm_group_label>LIK066</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching LIK066 tablets, for oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  PCOS (diagnosed as clinical or biochemical hyperandrogenism, amenorrhea or
             oligomenorrhea and exclusion of other causes of hyperandrogenism.

          -  Overweight/obese female subjects with BMI of 28 - 45 kg/m^2, inclusive, and stable
             weight +/- 3 kg over previous 3 months

          -  Subjects must use non-hormonal methods of contraception during the study.

        Key Exclusion Criteria:

          -  Subjects with exogenous causes of hirsutism

          -  Menstruation in the 30 days prior to screening or treatment

          -  Pregnant or nursing (lactating) women

          -  Use of prohibited medications

          -  Preexisting medical condition which may significantly alter the absorption,
             metabolism, or excretion of the study drug, or which may jeopardize the subject in
             case of participation in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>PCOS</keyword>
  <keyword>hyperandrogenism</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

